General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced a series of new ...

Genomics, Inc. (NASDAQ:TXG – Get Free Report) has received a consensus recommendation of “Hold” from the seventeen analysts ...

10x Genomics specializes in developing and manufacturing genomics analysis technologies, with a focus on single-cell and spatial genomics. The company's product portfolio includes the Chromium and ...

Q4 2024 Earnings Call Transcript February 12, 2025 10x Genomics, Inc. misses on earnings expectations. Reported EPS is $-0.4 ...

Chromium Consumables Revenue (Q4 2024): $97.7 million ... Revenue Guidance (2025): $610 million to $630 million, representing ...

Genomics reported a Q4 EPS loss of $(0.40), missing estimates, while revenue declined 10% year over year. Analysts lowered ...

Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by Morgan Stanley from $28.00 to $26.00 in a research ...

10x Genomics specializes in developing and manufacturing genomics analysis technologies, with a focus on single-cell and spatial genomics. The company's product portfolio includes the Chromium and ...

10x Genomics disclaims any intention or obligation ... I'll start with the product innovations we introduced in 2024. First on our Chromium platform. Last year was the biggest year of Chromium ...